Frequency of cytochrome 450 (CYP2C9 and CYP2C19) genetic polimorphisms in patients with colorectal carsinoma;Kolorektal kanserli hastalarda sitokrom P450 (CYP2C9 ve CYP2C19) genetik polimorfizm sikliǧi

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi

Volumn 19, Issue 3, 2009, Pages 134-139

  Buyukdogan, Murat ^a   Boruban, M Cem ^a   Artac, Mehmet ^a   Demirel, Sennur ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

Asbestos; Colorectal carcinoma; Cyp2c9 and cyp2c19 polymorphizm; Cytochrome p450

Indexed keywords

ASBESTOS; CARCINOGEN; CYTOCHROME P450 2C; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CANCER PATIENT; CASE CONTROL STUDY; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; DEVELOPED COUNTRY; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; FAMILY HISTORY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HEREDITY; HETEROZYGOTE; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RISK FACTOR; SMOKING; STATISTICAL ANALYSIS;

EID: 72949108232     PISSN: 1306133X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Fenoglio-Presier CM, Pascal RR, Perzin KH. Tumors of the large and small intestine. AFIP 34: 261-262, 1990.
2. Clinton SK, Giovannucci EL. Nutrition in the Etiology and Prevention of Cancer. Cancer medicine. Holland JF Frei E, Bast RC, Kufe DW Morton DL Weichselbaum R(eds) Williams and Wilkins Baltimore: 465-494, 1997.
3. Özerol E. Cytochrom P 450 containing monooksigenase enzym systems. Journal of Tugut Özal Medical Center. 3: 257-275, 1996.
4. Pchelina O, Sofya N, Anastasiya E, et al. The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity of warfarin. Thromb Res 115: 199-203, 2005.
5. Aynacioǧlu S, Brockmüller J, Bauer S, et al. Frequency of Cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Cli Pharmacol. 48: 409-415, 1999.
6. Stubbins MJ, Harries LW, Smith G, et al. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics 6: 429-439, 1996.
7. Gaedigk A, Casley WL, Tyndale RF, et al. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Can J Physiol Pharmacol 79: 841-847, 2001.
8. Wang R, Liu L, Cheng H. Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. DMD 24: 786-791, 1995.
9. Landi S, Gemignani F, Moreno V, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphism and risk of colorectal cancer. Pharmacogenet Genomics 15: 535-546, 2005.
10. Le Marchand L. Combined influence of genetic and dietary factors on colorectal cancer in Japanese Americans. JNCI 26: 101-105, 1999.
11. Martinez C, Garcia-Martin E, Ladero JM, et al. High frequency of mutations related to impared CYP2C9 metabolism in a Caucasian population. Eur J Clin Pharmacol 57: 47-49, 2001.
12. Pang YS, Wong LP, Lee TC, et al. Genetic polymorphism of cytochrome 2 C19 in P450 healthy Malaysian subjects. Br J Clin. Pharmacol 58: 332-335, 2004.
13. Herman D, Dolzan V, Breskvar K. Genetic polymorphism of cytochrome P450 2 C9 and 2C19 in Slovenian population. Zdrav Vestn 72:347-351, 2003.
14. Scordo MG, Caputi AP, D'Arrigo C, et al. Allel and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 genetic polymorphism in an Italian population. Pharmacol Res 50: 195-200, 2004.
15. Jose R, Chandrasekaran A, Soya SS, et al. CYP2C9 and CYP2C19 genetic polymorphism: frequencies in the South Indian population. Fundam Clin Pharmacol 19:101-105, 2004.
16. Tabrizi A, Zehnbauer A, Brocki B, Mc Grath S, Freeman B. The frequency and effects of Cytochrome P450 CYP2C9 polimorphism in patients receiving warfarin. J Am Coll Surg 194: 267-273, 2002.
17. Ablin J, Cabili S, Eldor A, et al. Warfarin therapy is feasibl in CYP2C9*3 homozygous patients. Eur J Intern Med 15:22-27, 2004.
18. Martinez C, Garcia-Martin E, Ladero JM, et al. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk (Response to letter to editor). Carcinogenesis 23: 667-668, 2002.
19. Yasar U, Eliasson E, Dahl ML. Association of CYP2C9 genotypes leading to high enzyme activity and colorectal cancer risk (letter to editor). Carcinogenesis vol 23: 665, 2002.
20. Tamer L, Ercan B, Ercan S, et al. CYP2C19 Polymorphisms in Patients with Gastric and Colorectal Carcinoma. Int J Gastrointest Cancer 37: 1-5, 2006.
21. Bariş YI, Bilir N, Artvinli M, et al. An epidemiological study on an Anatolian village environmentally exposed to tremolite asbestos. Br J Ind Med 45: 838-840, 1988.
22. Aliyu O, Cullen M, Barnett M, et al. Evidence for excess colorectal cancer incidence amog asbestos-exposed men in beta-carotene and retinol efficacy trial. Am J Epidemiol 162: 868-878, 2005.